Multiscale phenotyping of cardiovascular disease has revealed diversity among patients that can be used to personalize pharmacotherapies and predict outcomes. Nonetheless, precision phenotyping for cardiovascular disease remains a nascent field that has not yet translated into widespread clinical practice despite its many potential advantages for patient care. Future endeavors that demonstrate improved pharmacotherapeutic responses and associated reduction in adverse events will facilitate mainstream adoption of precision cardiovascular phenotyping.
Keyphrases
- cardiovascular disease
- high throughput
- end stage renal disease
- clinical practice
- ejection fraction
- chronic kidney disease
- type diabetes
- newly diagnosed
- single cell
- prognostic factors
- electronic health record
- cardiovascular risk factors
- current status
- metabolic syndrome
- risk assessment
- coronary artery disease
- climate change
- patient reported
- human health
- insulin resistance
- weight loss